Sera Prognostics, Inc. (NASDAQ:SERA) Director Joshua Phillips Sells 12,710 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) Director Joshua Phillips sold 12,710 shares of the stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $7.40, for a total transaction of $94,054.00. Following the completion of the sale, the director now owns 5 shares of the company’s stock, valued at approximately $37. The trade was a 99.96 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Joshua Phillips also recently made the following trade(s):

• On Monday, January 13th, Joshua Phillips sold 12,163 shares of Sera Prognostics stock. The stock was sold at an average price of $6.39, for a total transaction of $77,721.57.

Sera Prognostics Trading Up 3.8 %

Shares of NASDAQ:SERA opened at $6.61 on Thursday. The business has a fifty day simple moving average of $7.44 and a 200 day simple moving average of $7.31. Sera Prognostics, Inc. has a 1 year low of $4.98 and a 1 year high of $12.35.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.09 million. During the same period in the previous year, the business earned ($0.23) earnings per share. Analysts expect that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sera Prognostics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp grew its position in Sera Prognostics by 100.2% in the second quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock worth $892,000 after acquiring an additional 75,441 shares in the last quarter. Rhumbline Advisers acquired a new stake in shares of Sera Prognostics in the 2nd quarter valued at $190,000. American Century Companies Inc. boosted its holdings in Sera Prognostics by 12.7% in the second quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock worth $152,000 after purchasing an additional 2,891 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Sera Prognostics during the second quarter worth $162,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Sera Prognostics during the second quarter worth $68,000. Institutional investors own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.